Compare FISV & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FISV | BIIB |
|---|---|---|
| Founded | 1984 | 1978 |
| Country | United States | United States |
| Employees | 38000 | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.7B | 27.3B |
| IPO Year | N/A | 1996 |
| Metric | FISV | BIIB |
|---|---|---|
| Price | $49.17 | $197.65 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 28 | 25 |
| Target Price | $146.17 | ★ $206.83 |
| AVG Volume (30 Days) | ★ 7.2M | 846.3K |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.15 |
| Revenue | N/A | ★ $9,890,600,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.94 | N/A |
| P/E Ratio | ★ $9.94 | $90.98 |
| Revenue Growth | N/A | ★ 2.22 |
| 52 Week Low | $47.37 | $121.06 |
| 52 Week High | $70.41 | $205.97 |
| Indicator | FISV | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 35.62 | 55.26 |
| Support Level | N/A | $184.00 |
| Resistance Level | $64.56 | $202.73 |
| Average True Range (ATR) | 2.19 | 5.72 |
| MACD | -0.60 | 0.04 |
| Stochastic Oscillator | 12.30 | 74.18 |
Fiserv is a leading provider of core processing and complementary services, such as electronic funds transfer, payment processing, and loan processing, for US banks and credit unions, with a focus on small and midsize banks. Following its 2019 merger with First Data, Fiserv also provides payment processing services to merchants. About 10% of the company's revenue is generated internationally.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).